- Vector Safety
- Gene Editing (Off) Targets
- Immune Repertoire
- Sequence Analysis
- Gene Expression
- Bioinformatics
Platform for DNA- or RNA-Fusion Sequences
GeneWerk GmbH provides highly sensitive platforms and bioinformatics to determine fusion sequences adjacent to known DNA or RNA fragments in minimal tissue samples down to the single cell level.
Applications include clonality and safety of (viral) vectors in gene therapy, on-target specificity of designer nucleases, immune repertoire studies in T cells and B cells and next generation sequencing (NGS).
GeneWerk’s unique worldwide experience in gene therapy studies, bioinformatics, NGS, and associated regulatory demands can help to build the solutions you need by individual consultation.
News
Sep 21 GeneWerk Announces Growth Equity Investment from Ampersand Capital Partners
Read more … GeneWerk Announces Growth Equity Investment from Ampersand Capital Partners
Jun 04 Insight into Spatial and Temporal Trends of SARS-CoV‑2 Infection Outbreak
Read more … Insight into Spatial and Temporal Trends of SARS-CoV‑2 Infection Outbreak